{"id":"W2626225244","doi":"10.1212/wnl.0000000000004313","title":"Alemtuzumab CARE-MS I 5-year follow-up","year":2017,"lang":"en","type":"article","venue":"Neurology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":223,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; Montreal Neurological Institute and Hospital","funders":"EMD Serono; University of Cambridge; Genentech; Grifols; Multiple Sclerosis Society; Sanofi Genzyme; Five Prime Therapeutics; Acorda Therapeutics; Canadian Institutes of Health Research; GW Pharmaceuticals; Multiple Sclerosis Society of Canada; Eli Lilly and Company; CSL Behring; GlaxoSmithKline; Biogen; Bayer HealthCare; Sanofi; Teva Pharmaceutical Industries","keywords":"Alemtuzumab; Medicine; Expanded Disability Status Scale; Adverse effect; Internal medicine; Clinical endpoint; Discontinuation; Pediatrics; Randomized controlled trial; Multiple sclerosis; Psychiatry","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000100823,0.0001281233,0.0003092931,0.00007284247,0.0003825356,0.00003030419,0.0002932145,0.0001150656,0.0002908378],"category_scores_gemma":[0.00113207,0.0001067901,0.0001045976,0.00002864581,0.0003308612,0.00005643624,0.0003277149,0.0003658728,0.0004166714],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002189999,"about_ca_system_score_gemma":0.00006478995,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003842909,"about_ca_topic_score_gemma":0.000398266,"domain_scores_codex":[0.9987621,0.00005965189,0.0001433851,0.0003461299,0.0002633466,0.000425366],"domain_scores_gemma":[0.9986005,0.00009386234,0.00007022623,0.0009474892,0.0001422022,0.0001457487],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.004802325,0.0001550257,0.8717421,0.0002045967,0.0002831846,0.0006788023,0.001657696,0.000003098033,0.02401998,0.0005885354,0.04082602,0.05503866],"study_design_scores_gemma":[0.004236722,0.001421337,0.8776535,0.000008850246,0.00003096119,0.00003033198,0.00002681657,0.00004977561,0.0008837755,0.0000313752,0.1155395,0.00008709539],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9381373,0.0001645505,0.000006984164,0.009043782,0.0007722639,0.0003205698,0.000009629377,0.00006953649,0.0514754],"genre_scores_gemma":[0.9969459,0.0002707493,0.0000979652,0.001169745,0.0003907775,0.00003858405,0.000006891761,0.00002444739,0.001055003],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07471347,"threshold_uncertainty_score":0.5355607,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0569578367612932,"score_gpt":0.3447063250614835,"score_spread":0.2877484883001903,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}